Upcycling of Convoluted Subsea Flexible Flowlines The project brings together Argenica, leading Australian research organisations, AusPep and others to collaborate on trying to solve this large unmet global health challenge. This project involves critical research to assess the efficacy of an Australian manufactured novel neuroprotective pharmaceutical, R18D, in protecting brain cells following mrmTBI.
Currently there are no pharmaceutical therapies available to these patients to reduce the impact on neurological outcomes. concussions) and moderate traumatic brain injury (collectively termed mrmTBI), is a serious public health issue across the globe, representing the greatest contribution to death and disability globally among all trauma-related injuries. The Australian Stroke Alliance estimates the plan will contribute 235,000 years of healthy life, 1700 new jobs and $15.6 billion in economic benefits to Australia by 2050.Ī novel therapeutic for the treatment of traumatic brain injuryĬonnectivity Traumatic Brain Injury Australia Limited Improving treatment selection and speed is a key part of the overall plan for better stroke care for all Australians – metro, regional and rural. These will enable faster and better diagnosis and treatment selection for acute stroke. This CRC-P enables prominent industry and research experts to collaborate on developing new AI-powered clinical decision support systems. Treating stroke is a complex and time-pressured task for clinicians. It is one of the nation’s biggest killers and a leading cause of major lifelong disability. In Australia, a new stroke occurs every 19 minutes.
Ingham Institute for Applied Medical Research
AI-powered clinical decision assistance for acute strokeĪpollo Medical Imaging Technologies Pty Ltd
0 kommentar(er)
